The rights issue is carried out to secure the necessary funding to complete the ongoing CARMA study and to advance preparations for the planned Phase I/Ib clinical trial of ELC 401, thereby safeguarding future clinical progress and establishing a solid foundation for continued long term value creation.

The rights issues is subject to approval by the extraordinary general meeting to be held on 8 May 2026. The rights issue is covered to 75.0 per cent by subscription undertakings and guarantee commitments.